| Released | Contributor | Author | Title | Pages | Price |
| 24-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 23-Nov-2009 | Argus Research Corporation | David Coleman | Vickers Weekly Insider, 11/23/09 | 52 |
$50 |
| 23-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for CHTP | 13 |
$25 |
| 23-Nov-2009 | Market Edge |
N/A
| Market Edge Equity Research Report | 4 |
$10 |
| 20-Nov-2009 | Pechala's Reports | Frantisek Pechala | CHELSEA THERAPEUTICS INTL LTD (CHTP=US) 12-months forecast | 1 |
$15 |
| 20-Nov-2009 | Pechala's Reports | Lubomir Pechala | CHELSEA THERAPEUTICS INTL LTD (CHTP=US) 2-weeks forecast | 1 |
$10 |
| 19-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: CHELSEA THERAPEU -- CHTP | 1 |
$4 |
| 19-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: ALSE , CVM , CHTP , CYCC , CUR -- DRUGS | 3 |
$4 |
| 19-Nov-2009 | Zacks Investment Research Inc. |
N/A
| CHELSEA THERAP (CHTP) Zacks Company Snapshot | 1 |
$10 |
| 17-Nov-2009 | EconomicInvestor |
N/A
| "The Economy Matters" Report for CHTP: the economy's impact on CHTP's price and risk, featuring the powerful EconomicInvestor Star Rating | 6 |
$15 |
0.29% Nasdaq 
Research Reports
